Chart of the Day: Clovis Oncology

Clovis Oncology (CLVS) made major headlines after plunging 72% or $71.80 just yesterday.  But what we’re seeing may just be another overreaction to news the FDA requested further information for efficacy analysis in drugs for the treatment of epidermal growth factor receptor (EFGR) T790M-positive lung cancer. While the company will provide the necessary information, it’s…